Abstract Details

Title Steady State Pharmacokinetics of Formulations of XP23829, a Novel Prodrug of Monomethyl Fumarate (MMF), in Healthy Subjects

Topic Multiple Sclerosis

Presentation(s) (-)

Poster/Presentation
Number 188

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Dmitri V. Lissin, MD (Scilex Holding) PRESENTER	Dr. Lissin has received personal compensation in the range of $500,000-$999,999 for serving as a Chief Medical Officer with Scilex Holding .
Roman Herzig, MD, PhD (Palacky University, Faculty of Medicine and Dentistry)	Roman Herzig, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. Roman Herzig, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Boehringer Ingelheim . Roman Herzig, MD, PhD has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Care Comm.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Kenneth Cundy, PhD	No disclosure on file

�鶹��ýӳ��